Is the Watchman Procedure Covered by Medicare?

Medicare has covered the Watchman left atrial appendage closure procedure since 2016, when the Centers for Medicare and Medicaid Services (CMS) issued a national coverage determination for the device. The procedure is designed for people with atrial fibrillation who need stroke prevention but cannot safely take long-term blood thinners. Coverage comes with specific eligibility requirements that go beyond a simple diagnosis, and the out-of-pocket costs for Medicare beneficiaries, while real, tend to be lower over time than the ongoing expense of anticoagulant medications.

What the Watchman Procedure Does and Who It Is For

The Watchman is a small, umbrella-shaped device implanted in the heart’s left atrial appendage, a small pouch where blood clots tend to form in people with atrial fibrillation. By sealing off that pouch, the device reduces stroke risk without requiring lifelong use of blood-thinning drugs like warfarin or newer oral anticoagulants. The implant is done through a catheter threaded up from a vein in the leg, so it does not require open-heart surgery.

Medicare’s coverage is not a blanket approval for anyone with atrial fibrillation. CMS tied its 2016 national coverage determination to a specific set of clinical criteria. In broad terms, the patient must have non-valvular atrial fibrillation, face a meaningful stroke risk, and have a documented reason why long-term anticoagulation is problematic. That reason might be a history of serious bleeding events, a high fall risk, or an inability to maintain stable anticoagulant therapy. In the large Medicare population studied after 2016, roughly 42% of Watchman recipients had a history of prior major bleeding, which illustrates the kind of patient profile CMS had in mind.¹

The Shared Decision-Making Requirement

One of the most unusual aspects of Medicare’s Watchman coverage is a mandatory shared decision-making step. Before the procedure can go forward, the patient must meet with a physician who is not the one performing the implant. This independent physician reviews the risks and benefits with the patient, and the conversation must be formally documented. CMS built this requirement directly into its coverage criteria, making it one of the few cardiovascular procedures with such a mandate.²

In practice, this means your implanting cardiologist cannot simply schedule the procedure after a single office visit. You will need a separate appointment with another qualified physician, often a general cardiologist or internist, who independently confirms that you understand what the device does, what the alternatives are, and what complications could arise. The documentation from that meeting becomes part of the medical record that supports Medicare’s coverage decision. If the shared decision-making step is skipped or poorly documented, coverage could be denied after the fact, leaving the patient financially exposed.

What Medicare Beneficiaries Actually Pay

The total hospitalization cost for a Watchman implant runs in the range of about $24,600 at the median for Medicare-insured patients, though there is meaningful variation from hospital to hospital.³ Medicare covers the bulk of that, but the beneficiary’s share depends on their specific plan. Under Original Medicare (Parts A and B), you would typically owe the Part A inpatient deductible for the hospital stay and a 20% coinsurance on the physician services billed under Part B. If you have a Medigap supplemental policy, much or all of that coinsurance may be picked up.

The real financial picture, though, plays out over years rather than at the time of the procedure. One analysis comparing patient out-of-pocket costs across stroke-prevention strategies found that by five years, Watchman recipients had spent about $4,764 total, compared to roughly $7,146 for patients on newer oral anticoagulants and $6,453 for those on warfarin.⁴ The Watchman’s costs are front-loaded at the time of the procedure, but because there is no ongoing prescription expense afterward, the cumulative cost to the patient crossed below the cost of anticoagulant drugs by roughly year three or four. A separate analysis using earlier cost data found a similar crossover pattern, with out-of-pocket costs for the device becoming lower than warfarin at two years and lower than rivaroxaban at three years.⁵

These savings assume you actually stop taking anticoagulants after the device is implanted and confirmed to be working. Patients who remain on blood thinners for other reasons would not see the same financial benefit.

Medicare Advantage Plans and Prior Authorization

If you are enrolled in a Medicare Advantage plan rather than Original Medicare, coverage for the Watchman still applies because the CMS national coverage determination sets a floor that all Medicare plans must honor. However, Medicare Advantage plans often layer on their own prior authorization requirements. You may need pre-approval before the procedure is scheduled, and the plan may require specific documentation, including the shared decision-making record, before granting it. Denials and appeals are more common in the Advantage space, so it is worth confirming coverage in writing before the procedure date.

The variation in hospitalization costs is also worth noting. Among Medicare patients, about 13% of the cost differences from one hospital to another were attributable to center-level factors rather than patient characteristics, while for non-Medicare patients that figure was closer to 22%.³ In other words, Medicare’s standardized payment structure helps smooth out some of the wild price swings you might see with private insurance, though the patient’s coinsurance share can still vary depending on the facility.

Why the Hospital and Doctor You Choose Matters

Medicare covers the Watchman at facilities that meet CMS criteria, but not every hospital that performs the procedure does so equally well. A study of more than 87,000 patients across 693 hospitals found an overall procedural success rate of about 94%, but outcomes varied significantly by volume. Hospitals and physicians performing the most implants had the highest success rates, while lower-volume centers had meaningfully lower odds of a successful procedure.⁶

The gap was not trivial. Compared to the highest-volume hospitals, the lowest-volume quartile had about a third lower odds of procedural success. Physician volume showed a similar gradient, with doctors who performed the fewest procedures having the lowest success rates even after accounting for patient characteristics. CMS’s coverage criteria do require that the implanting physician and facility participate in a national outcomes registry, which creates some quality floor, but the volume-outcome relationship suggests that patients benefit from seeking out experienced centers. If your cardiologist recommends the Watchman but practices at a hospital that does only a handful per year, asking about higher-volume alternatives is a reasonable conversation to have.

The Registry Requirement

Part of CMS’s coverage conditions is that each Watchman implant must be entered into an approved national registry. The primary registry used is the National Cardiovascular Data Registry’s Left Atrial Appendage Occlusion Registry, which tracks procedural details, complications, and follow-up outcomes across participating hospitals.⁷ This is not optional paperwork. If the facility does not participate in the registry, the procedure is not covered under the national coverage determination.

The registry requirement serves two purposes. For CMS, it provides ongoing real-world safety and effectiveness data that supplements the original clinical trial evidence. For patients, it means that outcomes at your hospital are being tracked and compared against a national benchmark. The registry data has been the basis for several large studies that have shaped ongoing understanding of how the device performs outside of carefully controlled trial settings.

Long-Term Outcomes in the Medicare Population

Because the Watchman has been covered by Medicare since 2016, there is now meaningful data on how recipients fare over several years. A study of nearly 49,000 Medicare fee-for-service beneficiaries who received the device between 2016 and 2020 found that by five years, 44% had died, 15% had experienced a major bleeding event, and 7% had an ischemic stroke.¹ Those numbers deserve context: the patients in this study were elderly (median age 77), had multiple medical conditions, and were selected specifically because they had trouble tolerating blood thinners. The 44% five-year mortality rate reflects the overall health burden of this population, not a complication of the device itself.

Men had somewhat higher five-year mortality than women (about 47% versus 41%), but rates of ischemic stroke and major bleeding were similar between sexes.¹ Bleeding risk was highest in the period shortly after implantation, when patients are still on a short course of blood thinners while the device heals into place, and then declined over time.

What Happens After the Implant

Medicare’s coverage extends beyond the implant itself to the necessary follow-up care. After the Watchman is placed, patients typically take a combination of blood-thinning and antiplatelet medications for several weeks to a few months while heart tissue grows over the device. A follow-up imaging study, usually a transesophageal echocardiogram performed roughly 45 days after the procedure, checks whether the device is properly sealed. If it is, the blood thinner is discontinued, and the patient transitions to aspirin alone or stops anticoagulation entirely.

The question of when to stop anticoagulation after implantation has generated real clinical interest. A large study of patients who underwent surgical left atrial appendage closure (a related but different approach from the catheter-based Watchman) found that about 14% discontinued anticoagulation earlier than the standard protocol. Those patients had a slightly higher five-year rate of blood clots reaching the brain (about 6% versus 5%), but their risk of major bleeding was substantially lower, and the overall composite of death, clot events, and bleeding was identical between the two groups.⁸ The tradeoff between clot risk and bleeding risk is exactly what makes post-procedure management a nuanced discussion between you and your cardiologist rather than a one-size-fits-all protocol.

Disparities in Who Gets the Procedure

Medicare covers the Watchman regardless of a beneficiary’s race, ethnicity, or income level, but access is not equal in practice. A study examining zip-code-level data found that rates of left atrial appendage closure procedures were lower in areas with lower median household incomes and in zip codes with higher proportions of Black or Hispanic residents, even after adjusting for age and clinical conditions that would make someone a candidate for the device.⁹

The reasons are likely layered. The Watchman is performed at specialized cardiac catheterization labs that tend to be concentrated in larger medical centers, and those centers are not evenly distributed geographically. The shared decision-making requirement, while valuable for patient autonomy, adds an extra appointment that may be harder to arrange for people with transportation barriers or inflexible work schedules. Referral patterns also play a role: if a primary care physician or general cardiologist is not aware of the procedure or does not think to refer a patient who might qualify, coverage availability is irrelevant. The overwhelmingly White demographic profile of Watchman recipients in the Medicare data (93% in the large outcomes study) underscores how far access has to go before coverage translates into equitable use.¹

First-Generation Watchman Versus Watchman FLX

The original Watchman device (sometimes called Watchman 2.5) was the one evaluated in the clinical trials that led to CMS’s 2016 coverage decision. A newer version, the Watchman FLX, was subsequently cleared by the FDA and has been widely adopted. Medicare covers both versions under the same national coverage determination; the coverage criteria are based on the procedure and patient eligibility, not on which generation of the device is used.

The FLX was designed with changes intended to simplify implantation and reduce complications, and registry data has been used to compare the two devices head to head in real-world settings.⁷ From a coverage standpoint, the distinction between device generations does not affect whether Medicare pays. It may, however, affect which hospitals and physicians are best positioned to offer the procedure, since the transition to the newer device required operators to gain familiarity with different sizing and deployment techniques.

When Coverage Could Be Denied

Understanding the scenarios where Medicare might deny coverage is as important as knowing it generally covers the procedure. The most common reasons for denial or post-procedure clawback relate to documentation failures rather than clinical disagreement. If the shared decision-making meeting with an independent physician was not properly documented, if the patient did not meet the clinical criteria for stroke risk or anticoagulant intolerance, or if the facility was not participating in the required national registry, the claim can be rejected.

There are also clinical situations where the procedure might be appropriate from a medical standpoint but fall outside the current CMS criteria. Patients with valvular atrial fibrillation, for example, are generally not covered, because the original clinical trials focused on non-valvular atrial fibrillation. Patients who tolerate blood thinners well and have no documented reason to stop taking them may also fall outside the coverage criteria, even if they would prefer a device over lifelong medication. In those cases, Medicare would view the procedure as elective rather than medically necessary.

If you receive a denial, the standard Medicare appeals process applies. The first step is typically a redetermination request, followed by reconsideration by a qualified independent contractor, and further levels of appeal if needed. Having thorough documentation from the shared decision-making meeting and from the implanting physician’s assessment of why anticoagulation is problematic for you is the strongest foundation for a successful appeal.

1
PubMed Central. Long-Term Clinical Outcomes Following the WATCHMAN Device Use in Medicare Beneficiaries – Section: Results
2
PubMed Central. Medicare Mandates for Shared Decision Making in Cardiovascular Device Placement
3
PubMed Central. Center-Related Variation in Hospitalization Cost for Patients Undergoing Percutaneous Left Atrial Appendage Occlusion
4
PubMed Central. Comparative Costs to Medicare and Medicare Beneficiaries of Alternative AF Stroke Risk Reduction Strategies – Section: Abstract
5
Circulation. Medicare Budget Implications of Left Atrial Appendage Closure for Stroke Risk Reduction in Non-Valvular Atrial Fibrillation – Section: Abstract
6
Circulation: Cardiovascular Interventions. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
7
PubMed. Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices – Section: Methods
8
The Annals of Thoracic Surgery. Early Discontinuation of Long-Term Anticoagulation After Surgical Left Atrial Appendage Occlusion
9
PubMed Central. Racial, Ethnic, and Socioeconomic Inequities in Access to Left Atrial Appendage Occlusion – Section: Results